NEW YORK, June 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT, Financial), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following investor conference:
- Goldman Sachs 39th Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 12, 2018
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT: For more information about
Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
